TD-6450: Phase IIa started

Trek began a double-blind, U.S. Phase IIa trial to evaluate 60 and 120 mg TD-6450 once daily with 120 mg oral faldaprevir once daily and ribavirin twice daily for 12 weeks in about 24 treatment-naive ...